- Home
- CCIF vs QNCX Comparison
CCIF vs QNCX Comparison
Compare CCIF & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- QNCX
- Stock Information
- Founded
- CCIF 2011
- QNCX 2012
- Country
- CCIF United States
- QNCX United States
- Employees
- CCIF N/A
- QNCX N/A
- Industry
- CCIF Finance/Investors Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCIF Finance
- QNCX Health Care
- Exchange
- CCIF Nasdaq
- QNCX Nasdaq
- Market Cap
- CCIF 110.4M
- QNCX 88.6M
- IPO Year
- CCIF N/A
- QNCX 2019
- Fundamental
- Price
- CCIF $5.17
- QNCX $1.70
- Analyst Decision
- CCIF
- QNCX Strong Buy
- Analyst Count
- CCIF 0
- QNCX 4
- Target Price
- CCIF N/A
- QNCX $7.75
- AVG Volume (30 Days)
- CCIF 76.9K
- QNCX 343.3K
- Earning Date
- CCIF 01-01-0001
- QNCX 11-12-2025
- Dividend Yield
- CCIF 25.90%
- QNCX N/A
- EPS Growth
- CCIF N/A
- QNCX N/A
- EPS
- CCIF N/A
- QNCX N/A
- Revenue
- CCIF N/A
- QNCX N/A
- Revenue This Year
- CCIF N/A
- QNCX N/A
- Revenue Next Year
- CCIF N/A
- QNCX N/A
- P/E Ratio
- CCIF N/A
- QNCX N/A
- Revenue Growth
- CCIF N/A
- QNCX N/A
- 52 Week Low
- CCIF $7.43
- QNCX $0.72
- 52 Week High
- CCIF $10.16
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CCIF 37.21
- QNCX 49.01
- Support Level
- CCIF $5.13
- QNCX $1.44
- Resistance Level
- CCIF $5.27
- QNCX $1.84
- Average True Range (ATR)
- CCIF 0.09
- QNCX 0.12
- MACD
- CCIF 0.01
- QNCX 0.00
- Stochastic Oscillator
- CCIF 19.23
- QNCX 62.50
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.